Treating chemotherapy-induced anemia following the revised labeling for ESAs

Community Oncology

Volumn 6, Issue 6, 2009, Pages 279-282

  Shord, Stacy S ^a   Auerbach, Michael ^b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b Auerbach Hematology and Oncology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; ANTINEOPLASTIC AGENT; HEMOGLOBIN; IRON; IRON DEXTRAN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; CANCER INCIDENCE; CANCER MORTALITY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED ANEMIA; CLINICAL TRIAL; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG LABELING; DRUG SAFETY; ERYTHROCYTE PRESERVATION; ERYTHROCYTE TRANSFUSION; HEMOGLOBIN BLOOD LEVEL; HUMAN; IRON OVERLOAD; IRON THERAPY; NONHUMAN; REVIEW; UNITED STATES; VENOUS THROMBOEMBOLISM;

EID: 67649259215     PISSN: 15485315     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1548-5315(11)70353-9     Document Type: Review

References (43)

1. Ludwig H, Van Belle S, Barrett-Lee P, et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004;40:2293-2306. (Pubitemid 39348881)
2. Witzig TE, Silberstein PT, Loprinzi CL, et al. Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol 2005;23:2606-2617. (Pubitemid 46179449)
3. Procrit [prescribing information]. Raritan, NJ: Ortho Biotech, L.P.; 2008.
4. Aranesp [prescribing information]. Thousand Oaks, CA: Amgen Inc.; 2008.
5. Glaspy J, Vadhan-Raj S, Patel R, et al. Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial. J Clin Oncol 2006;24:2290-2297. (Pubitemid 46630659)
6. Schwartzberg LS, Yee LK, Senecal FM, et al. A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer. Oncologist 2004;9:696-707. (Pubitemid 39546409)
7. Senecal FM, Yee L, Gabrail N, et al. Treatment of chemotherapy-induced anemia in breast cancer: results of a randomized controlled trial of darbepoetin alfa 200 microg every 2 weeks versus epoetin alfa 40,000 U weekly. Clin Breast Cancer 2005;6:446-454. (Pubitemid 43078901)
8. Waltzman R, Croot C, Justice GR, et al. Randomized comparison of epoetin alfa (40,000 U weekly) and darbepoetin alfa (200 microg every 2 weeks) in anemic patients with cancer receiving chemotherapy. Oncologist 2005;10:642-650.
9. Abels RI, Larholt KM, Krantz KD, et al. Recombinant human erythropoietin (rHuEPO) for the treatment of the anemia of cancer. Oncologist 1996;1:140-150. (Pubitemid 126669230)
10. Cascinu S, Fedeli A, Del Ferro E, et al. Recombinant human erythropoietin treatment in cisplatin-associated anemia: a randomized, double-blind trial with placebo. J Clin Oncol 1994;12:1058-1062. (Pubitemid 24145337)
11. Case DC, Jr., Bukowski RM, Carey RW, et al. Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy. J Natl Cancer Inst 1993;85:801-806. (Pubitemid 23150311)
12. Hedenus M, Adriansson M, San Miguel J, et al. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol 2003;122:394-403. (Pubitemid 36951623)
13. Henry DH, Brooks BJ Jr, Case DC Jr, et al. Recombinant human erythropoietin therapy for anemic cancer patients receiving cisplatin chemotherapy. Cancer J Sci Am 1995;1:252.
14. Kotasek D, Steger G, Faught W, et al. Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy: results of a double-blind, placebo-controlled, randomised study. Eur J Cancer 2003;39:2026-2034. (Pubitemid 37297759)
15. Littlewood TJ, Bajetta E, Nortier JWR, et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001;19:2865-2874. (Pubitemid 32538196)
16. Crawford J, Cella D, Cleeland CS, et al. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 2002;95:888-895. (Pubitemid 34839682)
17. Rizzo JD, Lichtin AE, Woolf SH, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 2002;20:4083-4107.
18. Bennett CL. The Blue Cross Blue Shield assessment technology review: summary of findings. Best Pract Res Clin Haematol 2005;18:423-431. (Pubitemid 40425354)
19. Lyman GH, Glaspy J. Are there clinical benefits with early erythropoietic intervention for chemotherapy-induced anemia? Cancer 2006;106:223-233.
20. Bohlius J, Langensiepen S, Schwarzer G, et al. Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis. J Natl Cancer Inst 2005;97:489-498. (Pubitemid 40590430)
21. Agency for Healthcare Research and Quality. Comparative effectiveness of epoetin and darbepoetin for managing anemia in patients undergoing cancer treatment. May 23, 2006. http://effectivehealthcare.ahrq.gov/. Accessed May 12, 2009.
22. FDA Briefing Document, March 13, 2008, Oncologic Drugs Advisory Committee. www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4345b2-01-FDA.pdf. Accessed May 12, 2009.
23. Seidenfeld J, Piper M, Flamm C, et al. Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials. J Natl Cancer Inst 2001;93:1204-1214. (Pubitemid 32816195)
24. Baribeault DM. Evaluation of a change in prescribing patterns of darbepoetin alfa on red blood cell transfusion requirements in patients with chemotherapy-induced anemia. Pharmacotherapy (ACCP annual meeting abstracts) 2008;28. Abstract 156.
25. Vekeman F, Bookhart BK, Duh M, et al. Impact of limiting erythropoiesis-stimulating agent use for chemotherapy-induced anemia on the United States blood supply. Transfusion (AABB annual meeting abstracts) 2008;47:1951-1929A. Abstract 789.
26. Panagopoulos ND, Karakantza M, Koletsis E, et al. Influence of blood transfusions and preoperative anemia on long-term survival in patients operated for non-small cell lung cancer. Lung Cancer 2008;62:273-280.
27. Upile T, Jerjes W, Sandison A, et al. The direct effects of stored blood products may worsen prognosis of cancer patients; shall we transfuse or not? an explanation of the adverse oncological consequences of blood product transfusion with a testable hypothesis driven experimental research protocol. Med Hypotheses 2008;71:489-492.
28. Koch CG, Li L, Sessler DI, et al. Duration of red-cell storage and complications after cardiac surgery. N Engl J Med 2008;358:1229-1239.
29. Weber R, Jabbour N, Martin R. Anemia and transfusions in patients undergoing surgery for cancer. Ann Surg Oncol 2008;15:34-45.
30. Auerbach M, Ballard H, Trout JR, et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol 2004;22:1301-1307. (Pubitemid 41079845)
31. Auerbach M, Silberstein PT, Webb RT, et al. Darbepoetin alpha 500 mcg or 300 mcg once every three weeks with or without iron in patients with chemotherapy-induced anemia. Ann Oncol (ESMO Congress Abstracts) 2008;19(suppl 8). Abstract LBA9.
32. Bastit L, Vandebroek A, Altintas S, et al. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol 2008;26:1611-1618.
33. Hedenus M, Birgegard G, Nasman P, et al. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study. Leukemia 2007;21:627-632. (Pubitemid 46444544)
34. Henry DH, Dahl NV, Auerbach M, et al. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist 2007;12:231-242. (Pubitemid 46271625)
35. Kim YT, Kim SW, Yoon BS, et al. Effect of intravenously administered iron sucrose on the prevention of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy. Gynecol Oncol 2007;105:199-204. (Pubitemid 46441460)
36. Pedrazzoli P, Farris A, Del Prete S, et al. Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alfa. J Clin Oncol 2008;26:1619-1625.
37. Chertow GM, Mason PD, Vaage-Nilsen O, et al. On the relative safety of parenteral iron formulations. Nephrol Dial Transplant 2004;19:1571-1575. (Pubitemid 38796422)
38. Chertow GM, Mason PD, Vaage-Nilsen O, et al. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant 2006;21:378-382. (Pubitemid 43159991)
39. Henry DH, Dahl NV, Auerbach M. Is thromboembolism in cancer patients treated with erythropoietic stimulating agents related to thrombocytosis and iron restricted erythropoiesis? Blood 2007;110(11):1625.
40. Loo M, Beguin Y. The effect of recombinant human erythropoietin on platelet counts is strongly modulated by the adequacy of iron supply. Blood 1999;93:3286-3293. (Pubitemid 29220895)
41. Henry D, Dahl NV. Iron or vitamin B12 deficiency in anemic cancer patients prior to erythropoiesis-stimulating agent therapy. Commun Oncol 2007;4:95-101. (Pubitemid 46524416)
42. NCCN Clinical Practice Guidelines in Oncology. Cancer- and Chemotherapy-Related Anemia. v.3.2009. www.nccn.org. Accessed May 12, 2009.
43. Beguin Y, Maertens J, De Prijck B, et al. Darbepoetin-alfa and I.V. iron administration after autologous hematopoietic stem cell transplantation: a prospective randomized multicenter trial. Blood 2008;112((11):54.